Advancing the development of next-generation immunotherapies
Illuminating the immune landscape
ImmunoScape is an immunomics-focused company with a technology platform that allows for immune profiling and characterization of the human immune response at extremely high resolution.
The company’s Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information.
This technology has been utilized across multiple therapeutic areas, especially in oncology and infectious disease, both to better understand immunotherapy safety and efficacy and to identify drug targets.
Tops News & Media Coverage
ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors
TCR Upstart Gets Fresh Funding as it Looks to Charge Toward the Clinic
ImmunoScape Snags $14 Million for Technology Platform Targeting Cancer
ImmunoScape To Present at the 7th Annual CAR-TCR Summit
ImmunoScape Appoints Renowned Immuno-Oncology Expert Adrian Woolfson, BM BCh, PhD, to Board of Directors
ImmunoScape Expands its Executive and Scientific Teams to Extend Use of its Deep Immunomics Platform into Drug Discovery
ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery